Literature DB >> 16284458

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.

Omar Janneh1, Andrew Owen, Becky Chandler, Ruben C Hartkoorn, C Anthony Hart, Patrick G Bray, Stephen A Ward, David J Back, Saye H Khoo.   

Abstract

BACKGROUND: The efflux transporters P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRP) and breast cancer resistance protein (BCRP) limit the accumulation of antiretrovirals in cell lines but it is more important to know whether the expression of these transporters in peripheral blood mononuclear cells (PBMC) impacts cellular drug concentrations.
OBJECTIVES: To study the transport and accumulation of saquinavir (SQV) in PBMC and the effects of specific inhibitors of MRP1, MRP2, P-gp and BCRP.
METHODS: Transport and accumulation of [H]-SQV was measured in PBMC in the absence or presence of specific and non-specific inhibitors of MRP1, MRP2, P-gp and BCRP. Flow cytometric, western blot and real-time PCR assays were used to examine the relative expression of the drug efflux transporters in the same batches of PBMC.
RESULTS: MRP2 is present in PBMC. The expression of P-gp, MRP1, MRP2 (mRNA) and BCRP all displayed batch-to-batch variability. Specific and non-specific inhibitors of MRP1, P-gp and MRP2 significantly increased the baseline accumulation of SQV. Accumulation of SQV was not correlated with the expression of any single transporter.
CONCLUSIONS: Multiple drug efflux transporters are important in the intracellular accumulation of SQV in PBMC. If drug efflux contributes towards virological failure, then all contributing transporters will need to be inhibited.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284458     DOI: 10.1097/01.aids.0000194793.36175.40

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

Review 1.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

2.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.

Authors:  S L Hider; A Owen; R Hartkoorn; S Khoo; D Back; A J Silman; I N Bruce
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

4.  Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1.

Authors:  Jörn Lötsch; Sebastian Harder; Martin Stürmer; Hans-Wilhelm Doerr; Gerd Geisslinger; Schlomo Staszewski; Nils von Hentig
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

5.  Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.

Authors:  José Moltó; George Xinarianos; Cristina Miranda; Sudeep Pushpakom; Samandhy Cedeño; Bonaventura Clotet; Andrew Owen; Marta Valle
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

6.  Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.

Authors:  Olena Kis; Jason A Zastre; Md Tozammel Hoque; Sharon L Walmsley; Reina Bendayan
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

7.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

8.  Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

Authors:  Peter L Anderson; Christina L Aquilante; Edward M Gardner; Julie Predhomme; Patrick McDaneld; Lane R Bushman; Jia-Hua Zheng; Michelle Ray; Samantha MaWhinney
Journal:  J Antimicrob Chemother       Date:  2009-08-26       Impact factor: 5.790

9.  MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

Authors:  Mark Eilers; Upal Roy; Debasis Mondal
Journal:  Exp Biol Med (Maywood)       Date:  2008-06-05

10.  Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.

Authors:  Pär Matsson; Jenny M Pedersen; Ulf Norinder; Christel A S Bergström; Per Artursson
Journal:  Pharm Res       Date:  2009-05-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.